FoRx Therapeutics’ Post

Discover how personalised dosing can lead to improved outcomes in cancer care. Join experts in #oncology and #pharmacy to address key challenges and solutions. Don't miss Era of Personalized Medicine: What's Next? Personalised Dosing in Novel and Targeted Cancer Therapeutics, May 25 at 10:00 AM HKT. Register now: https://lnkd.in/eGZxBuKq

Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer: Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors. #finance #pharmacy #lifesciences

Discover how personalised dosing can lead to improved outcomes in cancer care. Join experts in #oncology and #pharmacy to address key challenges and solutions. Don't miss Era of Personalized Medicine: What's Next? Personalised Dosing in Novel and Targeted Cancer Therapeutics, May 25 at 10:00 AM HKT. Register now: https://lnkd.in/et-TjGuZ

Join CEO, David Regan, CMO Dr carman giacomantonio, and CSO Len Pagliaro for an exclusive webinar tomorrow at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment therapy, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT therapy, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Discover how personalised dosing can lead to improved outcomes in cancer care. Join experts in #oncology and #pharmacy to address key challenges and solutions. Don't miss Era of Personalized Medicine: What's Next? Personalised Dosing in Novel and Targeted Cancer Therapeutics, May 25 at 10:00 AM HKT. Register now: https://lnkd.in/diXGAcNz

We have come far to decrease cancer mainly in prostate and breast and increased FDA drug approvals as summarized by Dr. Rathmell Director National Cancer Institute. However much more is needed to help our patients! #ASCO2024 #cancer #Agilent #precisionmedicine

We’re thrilled to announce that #preclinicaldata highlighting the differentiating properties of MYTX-011, our investigational cMET-targeting #ADC, has been published in the latest issue of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. Learn more: https://lnkd.in/ezrt85xm.   Discover how MYTX-011 has the potential to benefit a broader set of patients by offering increased on-target potency, enhanced tolerability, a longer half-life and higher efficacy when compared to other ADCs. Read the full article here: https://lnkd.in/eM44ZFH4.  

Biolexis Therapeutics is answering the need for more effective treatments. Our clinical stage program, SLX-0528, targets RoRgT to suppress IL-17, thereby reducing immunotherapy adverse effects. We are also developing a CDK9 inhibitor, BLX-3030, to treat PDAC's and Neuroendocrine Pancreatic cancer. To learn more about or small molecule, AI driven pipeline, visit www.biolexistx.com #drugdiscovery #pancreaticcancer #pancreaticcancerawareness

Breastcancer.org and Smart Patients are sharing this with our communities. Will you? Resources like this spark conversation and play a pivotal role in enhancing relationships between HR+/HER2- breast cancer patients and their doctors, leading to several positive outcomes: 1. Improved Understanding of Treatment Options: This provides yet another comprehensive information tool on various treatment options, including hormonal therapies and targeted treatments. This knowledge empowers patients to have more informed discussions with their healthcare providers about their treatment plan. 2. Enhanced Decision-Making: With access to detailed information about their specific type of breast cancer, patients can better understand the implications of different treatment choices for more personalized and effective decision-making in line with their preferences and lifestyle. 3. Increased Confidence and Self-Advocacy: Well-informed patients are typically more confident in their interactions with healthcare professionals. They feel more equipped to ask pertinent questions, express concerns, and advocate for their needs and preferences. 4. Better Management of Side Effects: These resources include information on managing side effects of treatments to help patients to proactively discuss side effect management strategies with their doctors, leading to improved quality of life during treatment. 5. Enhanced Adherence to Treatment Plans: When patients understand the rationale behind their treatment regimen and what to expect, they are more likely to adhere to their prescribed treatments, leading to potentially better outcomes. 6. Long-term Health Planning: Resources can guide conversations about long-term health planning, including discussions about survivorship, lifestyle modifications, and monitoring for recurrence. Combine these resources with an oncologist prescription to peer-to-peer support from Smart Patients and you have a great package to address the psychological and emotional aspects of dealing with breast cancer, offering strategies for coping and maintaining mental well-being. Between Smart Patients and Breastcancer.org (and so many more beloved breast cancer patient support networks), we can support a more holistic conversation with healthcare providers, addressing the physical and emotional challenges of the disease. (kudos to Clinical Care Options, Eli Lilly and Company and Novartis)

Evaluating the Impact of Metastatic Breast Cancer on Patients: An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice. #finance #pharmacy #lifesciences